Referências bibliográficas:
1. Consenso da Sociedade Brasileira de Urologia 2017 – SBU.
2. Guidelines on Hypogonadism 2015 – EAU
3. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Task Force: Endocrine Society. Testoterone therapy in men with androgen deficienty syndomes: an Endrocine Society clinical pactice guideline. J Clin Endrocinol Metab. 2010;95(6):2536-2559.
4. Swerdloff RS et al. Long-term pharmacokinetics of transdermal testoterone gel in hypogonal men. J Clin Endocrinol Metab. 2000; 85: 4500-4510.
5. Wang C, et al. Long-term testoterone gel (Androgel) treatmeant maintains beneficial effects on sexual function and mood, lean and fat mass, and boné mineral density in hypogonal men. J Clin Endocrinol Metab. 2004 May; 89(5):2085-98. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/1512655. Acesso em 16/01/2020.
6. Bula do produto para paciente. Disponível em: http://www.anvisa.gov.br/datavisa/fila_bula/frmVisualizarBula.asp. Acesso em 21/01/2020.